Imagine living with a condition that not only affects your joints but also puts your kidneys at risk. That's the reality for many people with lupus nephritis, a serious complication of systemic lupus erythematosus. Treating this condition can be challenging, and current therapies don't always work well enough. Now, a new clinical trial is exploring whether cenerimod, a medication taken alongside regular treatments, can improve kidney function in adults with active lupus nephritis. Over 76 weeks, participants will take either cenerimod or a placebo—an inactive substitute—while regularly visiting the clinic for checkups. The hope is that cenerimod will lead to a complete renal response, meaning improved kidney health. If this trial shows positive results, it could offer new hope for lupus patients struggling with kidney issues. However, it’s important to remember that not all treatments work for everyone, and this trial is still in the early stages. Patients interested in participating should discuss it with their healthcare provider to understand the potential risks and benefits.
Phase 3 Trial of Cenerimod for Lupus Nephritis: Efficacy and Safety EvaluationCould a New Drug Help Improve Kidney Function in Lupus Patients?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Monitor for updates on cenerimod's efficacy in lupus nephritis treatment.
This Phase 3 clinical trial aims to evaluate the efficacy and safety of cenerimod in treating active lupus nephritis in adults with systemic lupus erythematosus. The study involves 300 participants who will receive either cenerimod or a placebo daily for 76 weeks, in addition to their regular treatment. The primary endpoint is the achievement of complete renal response (CRR), which will be assessed over the course of the study. Secondary endpoints include improvements in kidney function and the incidence of adverse events. Participants will attend clinic visits every 1 to 3 months for monitoring and assessments. The trial is sponsored by Viatris Innovation GmbH and is expected to complete primary data collection by August 2029. Safety evaluations will focus on the incidence and severity of adverse events associated with cenerimod. The results of this trial will provide valuable insights into the potential role of cenerimod as an adjunctive therapy for lupus nephritis.
What this means for you:
A new drug may offer hope for lupus patients by improving kidney function and overall health. More on Lupus Nephritis
STAT3 inhibition targets cytokine signaling and renal inflammation in systemic lupus erythematosus and lupus nephritis
New review suggests STAT3 inhibition could help lupus kidney disease
This narrative review examines the role of STAT3 in systemic lupus erythematosus and lupus nephritis. The authors argue that STAT3 integrate…
A narrative review suggests targeting STAT3 might treat lupus kidney inflammation, though direct drug targeting remains unproven in patients…
Tubulointerstitial inflammation and fibrosis predict renal function decline in adult lupus nephritis patients across multiple studies
Kidney damage in lupus is linked to specific tissue changes seen in scans
A systematic review of 3,607 adult patients reveals that tubulointerstitial inflammation and fibrosis significantly increase the risk of ren…
A large review found that kidney tissue changes called tubulointerstitial inflammation and fibrosis raise the risk of kidney failure in lupu…
Commentary on plateau in lupus nephritis trials and path to precision medicine
New lupus drugs hit a ceiling where kidney healing stops improving
This commentary reviews 200 interventional pharmacological trials in lupus nephritis. The authors note a persistent ceiling effect with comp…
Kidney healing in lupus patients using new drugs often stops improving after reaching a 40 to 50 percent success rate, limiting how much bet…
Network meta-analysis compares biologics and targeted drugs for systemic lupus erythematosus efficacy and safety
New Lupus Treatments Show Stronger Results With Fewer Side Effects
This systematic review and network meta-analysis of 17,121 patients with systemic lupus erythematosus compared biologics and targeted small …
Certain new lupus drugs help more people feel better with fewer flare-ups, especially those struggling with rashes or joint pain that older …
View Original Abstract ↓
Status: RECRUITING | Phase: PHASE3
Condition(s): Nephritis, Lupus, Lupus Erythematosus, Systemic
Intervention(s): Cenerimod (DRUG), Placebo (DRUG)
The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to answer are:
* Does cenerimod improve kidney function in participants?
* What medical problems do participants have when taking cenerimod?
Researchers will compare cenerimod to a placebo (a look-alike substance that contains no drug) to see how well cenerimod works when it is added to regular treatment.
Participants will:
* Take cenerimod or a placebo every day for 76 weeks (approximately 1.5 years), on top of regular treatment.
* Visit the clinic every 1 to 3 months for checkups and tests.
Primary Outcome(s): Complete renal response (CRR)
Enrollment: 300 (ESTIMATED)
Lead Sponsor: Viatris Innovation GmbH
Start: 2026-02-09 | Primary Completion: 2029-08
Late-onset rheumatoid arthritis shows higher DAS28 scores and lower remission rates compared to young-onset disease in a meta-analysis
Meta-analysis compares treatment outcomes in older versus younger rheumatoid arthritis patients
Related in Rheumatology
Long-term personalized exercise therapy shows potential cost-effectiveness for patients with axial spondyloarthritis
Personalized exercise therapy shows promise for axial spondyloarthritis patients
Researchers evaluated the cost-utility of long-term, personalized exercise therapy compared to usual care in patients with axial spondyloart…
New research looks at whether personalized, long-term exercise programs are a cost-effective way to manage severe axial spondyloarthritis.
EmiratesMEDs competency framework establishes 9 thematic roles and 14 EPAs for UAE medical education
New UAE framework sets 85 competencies for medical graduates
This guideline outlines the EmiratesMEDs competency framework designed to harmonize undergraduate medical education in the United Arab Emira…
A national competency framework for UAE medical graduates defines 85 skills and 14 clinical tasks to standardize education.
Esketamine significantly reduces postoperative anxiety (SMD -1.23) and depressive symptoms (SMD -0.92) in adult patients
Esketamine reduces anxiety and depression after surgery
This meta-analysis of 1,312 adults undergoing general anesthesia found that esketamine significantly reduced both anxiety and depression pos…
New data shows esketamine can significantly lower feelings of anxiety and depression in adults following surgery.
Machine learning and postoperative indicators improve AUC for predicting anastomotic leak in gastric cancer surgery
Machine Learning Models May Better Predict Gastric Cancer Complications
This systematic review and meta-analysis of 18 studies involving 15,783 patients evaluated risk prediction models for anastomotic leak. The …
New analysis shows machine learning models may offer better accuracy in predicting surgical complications for patients with gastric cancer.
From Other Specialties
Post-extubation dysphagia incidence ranges from 28.36% to 68.94% in critically ill children
High rates of swallowing problems found in children after intubation
This scoping review of 15 studies examines the incidence and predictors of pediatric post-extubation dysphagia (PED). The authors identify h…
Many critically ill children struggle to swallow safely after breathing tubes are removed, with some studies showing issues in up to 69% of …
Circular RNAs may regulate ferroptosis and anti-tumor immunity in cancer via multiple mechanisms
Circular RNAs may offer new ways to target cancer cells
This systematic review explores how circular RNAs (circRNAs) act as molecular bridges to simultaneously regulate ferroptosis and anti-tumor …
New research identifies circular RNAs as molecular bridges that could help doctors diagnose and treat cancer more precisely.
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …